-
- Dimitrios Sagris
- Department of Internal Medicine Faculty of Medicine School of Health Sciences University of Thessaly Larissa Greece
-
- Aikaterini Papanikolaou
- Department of Internal Medicine Faculty of Medicine School of Health Sciences University of Thessaly Larissa Greece
-
- Alexandra Kvernland
- Department of Neurology NYU Grossman School of Medicine New York NY USA
-
- Eleni Korompoki
- Department of Clinical Therapeutics National and Kapodistrian University of Athens Athens Greece
-
- Jennifer A. Frontera
- Department of Neurology NYU Grossman School of Medicine New York NY USA
-
- Andrea B. Troxel
- Department of Population Health NYU Grossman School of Medicine New York NY USA
-
- Maria Gavriatopoulou
- Department of Clinical Therapeutics National and Kapodistrian University of Athens Athens Greece
-
- Haralampos Milionis
- Department of Internal Medicine Faculty of Medicine School of Health Sciences University of Ioannina Ioannina Greece
-
- Gregory Y. H. Lip
- Liverpool Centre for Cardiovascular Science University of Liverpool and Liverpool Heart & Chest Hospital Liverpool UK
-
- Patrik Michel
- Stroke Center Neurology Service Lausanne University Hospital Lausanne Switzerland
-
- Shadi Yaghi
- Department of Neurology NYU Grossman School of Medicine New York NY USA
-
- George Ntaios
- Department of Internal Medicine Faculty of Medicine School of Health Sciences University of Thessaly Larissa Greece
説明
<jats:title>Abstract</jats:title><jats:p>Since the onset of the COVID‐19 pandemic, a substantial proportion of COVID‐19 patients had documented thrombotic complications and ischemic stroke. Several mechanisms related to immune‐mediated thrombosis, the renin angiotensin system and the effect of SARS‐CoV‐2 in cardiac and brain tissue may contribute to the pathogenesis of ischemic stroke in patients with COVID‐19. Simultaneously, significant strains on global healthcare delivery, including ischemic stroke management, have made treatment of stroke in the setting of COVID‐19 particularly challenging. In this review, we summarize the current knowledge on epidemiology, clinical manifestation, and pathophysiology of ischemic stroke in patients with COVID‐19 to bridge the gap from bench to bedside and clinical practice during the most challenging global health crisis of the last decades.</jats:p>
収録刊行物
-
- European Journal of Neurology
-
European Journal of Neurology 28 (11), 3826-3836, 2021-07-17
Wiley